A Pilot Study of CPX-351 (Vyxeos) for Transplant Eligible, Higher Risk Patients With Myelodysplastic Syndrome
Phase of Trial: Phase I
Latest Information Update: 21 Dec 2018
At a glance
- Drugs Cytarabine/daunorubicin (Primary)
- Indications Myelodysplastic syndromes
- Focus Adverse reactions
- 14 Dec 2018 Planned End Date changed from 30 Nov 2025 to 31 Dec 2025.
- 14 Dec 2018 Planned primary completion date changed from 30 Apr 2021 to 31 May 2021.
- 14 Dec 2018 Status changed from not yet recruiting to recruiting.